Bionxt fast-tracks MS drug patent, expands IP

Executive Summary

• Bionxt Solutions Inc. has initiated the USPTO's "Track One" prioritized examination program for its U.S. patent application for BNT23001, a sublingual thin-film cladribine formulation for multiple sclerosis (MS), aiming for a final decision in under seven months.
• The company secured acceptance of core claims for a broad international umbrella patent protecting its sublingual thin-film delivery technology across a wide range of autoimmune and neuroinflammatory indications, with exclusivity extending into the 2040s.
• Bionxt plans to initiate a preclinical pharmacokinetic (PK) study in pigs to demonstrate superbioavailability compared to Merck’s Mavenclad, which could qualify the drug for an accelerated regulatory path under the European hybrid application framework.

Key Details

• U.S. Patent Fast-Track: Bionxt entered the USPTO Track One program for BNT23001, targeting a first Office Action in ~2 months and a final disposition in under 7 months.
• BNT23001 Formulation: An orally dissolvable, sublingual thin-film formulation of cladribine designed for improved bioavailability, faster onset, and enhanced patient compliance (particularly for dysphagia patients).
• Target Indications: Relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and generalized myasthenia gravis (GMG).
• Competitive Context: Bionxt aims to compare its formulation against Merck KGaA’s Mavenclad (cladribine capsules), which generated >$1 billion (U.S.) in sales in 2023.
• Regulatory Strategy: If superior bioavailability is demonstrated, Bionxt seeks qualification for an accelerated regulatory path under Article 10a of the European hybrid application framework, requiring only comparative PK data in healthy volunteers.
• Preclinical Study: A preclinical PK study in pigs (a translational model for oral/sublingual absorption) will be initiated near-term to support regulatory positioning. Results expected later this year.
• International Patent Coverage: Core claims accepted by the European Patent Office (EPO) and Eurasian Patent Organization (EAPO). National-phase filings initiated in the U.S., Canada, Japan, Australia, and New Zealand.
• Patent Scope: The umbrella patent covers composition, manufacturing, administration methods, and use for a broad class of drug compounds beyond just cladribine, including targets such as NMOSD, autoimmune encephalitis, CNS vasculitis, optic neuritis, Hashimoto's encephalopathy, cerebral lupus, and Sjogren's syndrome.
• Market Sizing:
  • Global MS patients: >2.8 million (nearly 1 million in the U.S.).
  • U.S. MS drug market: $7.81 billion (2024), projected to reach $17.15 billion by 2034 (CAGR 8.18%).
  • GMG patients: ~700,000 globally.
  • Combined Total Addressable Market (TAM) for MS and GMG: $42–$46 billion (U.S.) by 2032.
  • Central nervous system therapeutics market projected to exceed $239 billion (U.S.) by 2032.

Notable Quotes

• No direct quotes from executives were included in the provided text.